Aethlon Medical (NASDAQ:AEMD) Now Covered by StockNews.com

StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD) in a research note released on Friday. The firm issued a sell rating on the medical equipment provider’s stock.

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a research report on Monday, March 10th.

Aethlon Medical Stock Performance

AEMD stock opened at $0.37 on Friday. The company’s fifty day moving average price is $0.56 and its 200-day moving average price is $0.50. Aethlon Medical has a one year low of $0.24 and a one year high of $1.79. The company has a market capitalization of $5.30 million, a PE ratio of -0.23 and a beta of 1.80.

Aethlon Medical (NASDAQ:AEMD) last released its quarterly earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.09. On average, research analysts predict that Aethlon Medical will post -0.73 EPS for the current fiscal year.

Institutional Trading of Aethlon Medical

Institutional investors and hedge funds have recently made changes to their positions in the company. Boothbay Fund Management LLC purchased a new stake in Aethlon Medical during the fourth quarter worth $186,000. Virtu Financial LLC bought a new position in shares of Aethlon Medical in the 4th quarter worth $81,000. Sassicaia Capital Advisers LLC purchased a new stake in shares of Aethlon Medical during the 4th quarter worth $31,000. Allegiance Financial Group Advisory Services LLC bought a new stake in Aethlon Medical during the fourth quarter valued at about $26,000. Finally, Renaissance Technologies LLC bought a new stake in Aethlon Medical during the fourth quarter valued at about $25,000. 1.99% of the stock is currently owned by institutional investors.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.